JP2021522247A5 - - Google Patents

Info

Publication number
JP2021522247A5
JP2021522247A5 JP2020559442A JP2020559442A JP2021522247A5 JP 2021522247 A5 JP2021522247 A5 JP 2021522247A5 JP 2020559442 A JP2020559442 A JP 2020559442A JP 2020559442 A JP2020559442 A JP 2020559442A JP 2021522247 A5 JP2021522247 A5 JP 2021522247A5
Authority
JP
Japan
Prior art keywords
composition according
solvate
phenyl
pharmaceutical composition
liver disease
Prior art date
Application number
JP2020559442A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522247A (ja
JPWO2019209738A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/028551 external-priority patent/WO2019209738A1/en
Publication of JP2021522247A publication Critical patent/JP2021522247A/ja
Publication of JPWO2019209738A5 publication Critical patent/JPWO2019209738A5/ja
Publication of JP2021522247A5 publication Critical patent/JP2021522247A5/ja
Pending legal-status Critical Current

Links

JP2020559442A 2018-04-24 2019-04-22 肝疾患における好中球エラスターゼ阻害薬の使用 Pending JP2021522247A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862662074P 2018-04-24 2018-04-24
US62/662,074 2018-04-24
PCT/US2019/028551 WO2019209738A1 (en) 2018-04-24 2019-04-22 Use of neutrophil elastase inhibitors in liver disease

Publications (3)

Publication Number Publication Date
JP2021522247A JP2021522247A (ja) 2021-08-30
JPWO2019209738A5 JPWO2019209738A5 (https=) 2022-04-27
JP2021522247A5 true JP2021522247A5 (https=) 2022-04-27

Family

ID=68236763

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020559442A Pending JP2021522247A (ja) 2018-04-24 2019-04-22 肝疾患における好中球エラスターゼ阻害薬の使用

Country Status (11)

Country Link
US (2) US10806735B2 (https=)
EP (1) EP3784657A4 (https=)
JP (1) JP2021522247A (https=)
KR (1) KR20210002573A (https=)
CN (1) CN113614070A (https=)
AU (2) AU2019257632A1 (https=)
CA (1) CA3101274A1 (https=)
IL (1) IL278207A (https=)
SG (1) SG11202010521VA (https=)
TW (1) TW202011965A (https=)
WO (1) WO2019209738A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
AU2020336272A1 (en) 2019-08-23 2022-04-14 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CN114375193B (zh) 2019-09-12 2024-05-14 拓臻制药公司 甲状腺激素受体β激动剂化合物
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
JP2023539639A (ja) 2020-08-25 2023-09-15 イーライ リリー アンド カンパニー Ｓｓａｏ阻害剤の多形
US20220098184A1 (en) * 2020-09-11 2022-03-31 Terms Pharmaceuticals, Inc. Solid dispersion formulations of an fxr agonist
CN114085173B (zh) * 2021-10-18 2024-04-16 嘉兴学院 一种2-硝基-4-甲砜基苯甲醛的制备方法
CN115976192A (zh) * 2022-12-02 2023-04-18 西安华壹健康医学检验实验室有限公司 一种用ne基因表达量检测评估脂肪肝的方法
CN117357508B (zh) * 2023-11-03 2024-05-17 中山大学孙逸仙纪念医院 西维来司他在制备治疗原发性胆汁性胆管炎的药物中的应用
CN119499379B (zh) * 2024-09-23 2025-09-05 广东医科大学 Elane基因作为心力衰竭靶点的制药用途和西维来司他的新用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8288402B2 (en) * 2007-12-20 2012-10-16 Bayer Intellectual Property Gmbh 4-(4-cyano-2-thioaryl)dihydropyrimidinones and their use
US9475779B2 (en) * 2014-07-31 2016-10-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
BR112017004708A2 (pt) * 2014-09-12 2017-12-05 Tobira Therapeutics Inc terapia de combinação de cenicriviroc para o tratamento de fibrose
WO2016050835A2 (en) 2014-10-02 2016-04-07 Ruprecht-Karls-Universität Heidelberg Selective inhibitors of neutrophil elastase for treating neuropathic pain and chronic pain states harbouring a neuropathic component
JP2018501276A (ja) * 2015-01-09 2018-01-18 ギリアド アポロ， エルエルシー 非アルコール性脂肪肝疾患の処置のためのａｃｃ阻害剤併用療法
CN110981815A (zh) * 2015-03-18 2020-04-10 Ph制药有限公司 用于生产化合物的方法
US10894054B2 (en) * 2015-04-07 2021-01-19 Intercept Pharmaceuticals, Inc. FXR agonist compositions for combination therapy
WO2017081044A1 (en) 2015-11-13 2017-05-18 Bayer Pharma Aktiengesellschaft 4-(4-cyano-2-thioaryl)dihydropyrimidinones for treating chronic wounds
GB201608453D0 (en) 2016-05-13 2016-06-29 Univ Liverpool Muscle regeneration
EP3518918A4 (en) * 2016-09-28 2020-04-22 Eiger Biopharmaceuticals, Inc. METHOD AND PHARMACEUTICAL COMPOSITIONS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS

Similar Documents

Publication Publication Date Title
JP2021522247A5 (https=)
JP2023002662A5 (https=)
CN104918613B (zh) 通过给予秋水仙碱衍生物治疗或预防心血管事件
JP5911929B2 (ja) 特定の癌の治療のためのｒｄｅａ１１９／ｂａｙ８６９７６６を含む組み合わせ医薬
JP2015528471A5 (https=)
US20240325356A1 (en) Prophylactic and therapeutic drug for nonalcoholic fatty liver disease
JP2020529995A5 (https=)
JP2019515909A5 (https=)
RU2019100037A (ru) Способ лечения рассеянного склероза с использованием ингибитора lsd1
JP2024095711A (ja) 可溶性グアニル酸シクラーゼ活性化薬としてのアルコキシピラゾール
JP2009511450A5 (https=)
JPWO2019209738A5 (https=)
CN101939001A (zh) 用于治疗卵巢癌的含有紫杉醇的组合
JP2020500868A5 (https=)
JP2005527575A5 (https=)
CN110755432A (zh) 烟酰胺在制备治疗手足皮肤反应制剂中的应用
CA2504665A1 (en) Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia
CN107072996A (zh) 血脂异常症治疗剂
JP2021521227A5 (https=)
JP2009532494A5 (https=)
AR126393A1 (es) Terapia combinada para el tratamiento de enfermedades hepáticas
RU2022107481A (ru) Применение ингибитора эластазы нейтрофилов при заболеваниях легких
RU2021130172A (ru) Способы лечения пограничного расстройства личности
RU2020109167A (ru) Способы лечения изменений поведения
RU2023109542A (ru) Способы лечения заболеваний, связанных с рибонуклеотидредуктазой, ингибитором рибонуклеотидредуктазы